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Abstract
Objectives To determine whether BCG vaccination protects against
Mycobacterium tuberculosis infection as assessed by interferon γ release
assays (IGRA) in children.
Design Systematic review and meta-analysis. Searches of electronic
databases 1950 to November 2013, checking of reference lists, hand
searching of journals, and contact with experts.
Setting Community congregate settings and households.
Inclusion criteria Vaccinated and unvaccinated children aged under
16 with known recent exposure to patients with pulmonary tuberculosis.
Children were screened for infection with M tuberculosis with interferon
γ release assays.
Data extraction Study results relating to diagnostic accuracy were
extracted and risk estimates were combined with random effects
meta-analysis.
Results The primary analysis included 14 studies and 3855 participants.
The estimated overall risk ratio was 0.81 (95% confidence interval 0.71
to 0.92), indicating a protective efficacy of 19% against infection among
vaccinated children after exposure compared with unvaccinated children.
The observed protection was similar when estimated with the two types
of interferon γ release assays (ELISpot or QuantiFERON). Restriction
of the analysis to the six studies (n=1745) with information on progression
to active tuberculosis at the time of screening showed protection against
infection of 27% (risk ratio 0.73, 0.61 to 0.87) compared with 71% (0.29,
0.15 to 0.58) against active tuberculosis. Among those infected,
protection against progression to disease was 58% (0.42, 0.23 to 0.77).
Conclusions BCG protects against M tuberculosis infection as well as
progression from infection to disease.
Trial registrationPROSPERO registration No CRD42011001698 (www.
crd.york.ac.uk/prospero/).
Introduction
BCG vaccine has been the subject of numerous efficacy trials
and epidemiological studies conducted over several decades.
These trials indicate that BCG has 60-80% protective efficacy
against severe forms of tuberculosis in children, particularly
meningitis,1 2 and its efficacy against pulmonary diseases varies
geographically.3-5BCG does not seem to protect against disease
when it is given to people already infected or sensitised to
environmental mycobacteria, which could explain the
geographical variation.6-8 Until recently it was not possible to
establish whether the protective effect of BCG vaccination
against disease was from its action in preventing acquisition of
infection or limited to prevention of progression from infection
to clinical disease.
The scarcity of evidence on whether the vaccine is effective
against Mycobacterium tuberculosis infection was because of
limitations of the tuberculin skin test. This test cannot distinguish
a positive response caused by M tuberculosis infection from
that caused by BCG vaccination or non-tuberculous
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mycobacterial infection.9 The recently developed T cell based
interferon γ release assays (IGRA) can detect M tuberculosis
infection and discriminate this from previous BCG vaccination
and most non-tuberculous mycobacterial infections,10 allowing
investigation of whether BCG protects against M tuberculosis
infection.11-13 If BCG is found to protect against infection, it will
have key implications for its use in current immunisation
programmes14 as well as in the future development of new
improved tuberculosis vaccines.
In this systematic review we examined the evidence for the
protective effect of BCG against M tuberculosis infection, as
opposed to against disease, in settings where children can be
presumed to have been exposed toM tuberculosis. This therefore
assesses the degree to which BCG vaccination before exposure
is associated with a subsequent negative result on an interferon
γ release assay. We also looked at factors that could alter the
measured protective effect of BCG: latitude, the recommended
age of vaccination in the area where the study was conducted,
type of assay, and study quality. When there was sufficient
information, we determined protection against early progression
from infection to disease during screening.
Methods
Search and Data Extraction
We searched Embase (1980 until November 2013), Medline
(1950 until November 2013), and the Cochrane Library as well
as reference lists of retrieved articles and conference abstracts.
The search strategy was not restricted by language or year. We
used the following search terms, adapted for each database when
appropriate: BCG, Bacillus Calmette Guerin, tuberculosis, TB,
interferon γ release assay, IGRA, ELI Spot, T-Spot TB, and
QuantiFERON. We also reviewed the personal libraries of the
research team. Two reviewers (AR and ME) independently
screened the titles and abstracts (when available) from the search
results and identified studies for assessment of full text.
Disagreements were resolved by asking the opinion of a third
reviewer (IA) for resolution until consensus was reached at each
stage of the screening process.
Information extracted onto pretested data forms included study
details (authors, year, geographical area, study design, sample
size), the population (mean age, sex, and setting), exposure
(method of assessment and timing), and two outcomesmeasures:
interferon γ release assays (as a proxy for tuberculosis infection)
and active tuberculosis (when reported). When relevant
information was missing, we contacted study authors by email.
For some studies, the stated primary outcome was not M
tuberculosis infection but data on results of interferon γ release
assays had been collected. For these studies, we contacted the
authors to obtain the raw data.
Inclusion and exclusion criteria
Studies meeting the following criteria were included:
• Participants had known recent exposure to people with
pulmonary tuberculosis. We assumed that in such studies,
a reduced rate of infection in vaccinated versus
unvaccinated children could be attributed to protection by
vaccination rather than lack of exposure.
• Participants were children aged under 16, including those
who had and had not been vaccinated with BCG.
• All children were screened for infection with M
tuberculosiswith interferon γ release assays; either in tube
γ interferon quantification (QuantiFERON) or enumeration
of γ interferon releasing T cells (ELISpot).
• We excluded all studies in which interferon γ release assays
was used only in children with positive results from
tuberculin skin test or in which participants were not tested
by interferon γ release assays or when the study reported
on active tuberculosis or results of tuberculin skin test only
or where the study was conducted in animals.
Quality assessment for individual studies
Two reviewers (AR and ME) assessed aspects of the quality of
each selected study using a modified version of the
Newcastle-Ottawa scale for assessment of observational cohort
studies.15 This scale awards a maximum of nine points to each
study: four points for the adequate selection of participants, two
points for comparability of the studies based on the design and
analysis, and three points for the adequate ascertainment of
outcome.We defined studies of high quality as those that scored
≥66.6%, moderate for 33.3-66.6%, and low for those <33.3%.
Discrepancy in quality assessment was discussed and resolved
by the two reviewers.
Definitions
• Exposure to tuberculosis was defined as close contact with
people with active pulmonary tuberculosis as identified by
the treating physicians.
• Infection was defined as any positive results of interferon
γ release assays in contacts irrespective of whether they
had evidence of active tuberculosis or not. Participants
with an indeterminate status were excluded from the
analysis.
• Disease was defined as presence of active tuberculosis
(according to the authors) with or without a positive result
on interferon γ release assays. Outcomes of both infection
and active disease were identified at the point of screening
for infection after exposure. A small number of additional
cases might have been included as some outbreak
investigations were undertaken over a period of several
weeks.
Synthesis of results
Primary analysis—protection against infection
Our primary analysis focused on whether BCG vaccination
administered before exposure was associated with a subsequent
negative result on interferon γ release assay in children who
had contact with infectious tuberculosis. We used binary data
to categorise participants into those who were or were not
vaccinated with BCG and those who did or did not have a
negative assay result (independent of progression to disease),
with continuity corrections applied to zero cells.16 To include
all studies in a single analysis, we combined results from studies
reporting both QuantiFERON and ELIspot. Where results of
both assays were available from a study we chose the
QuantiFERON result as this was most used among the selected
studies.
Subgroup analyses of protection against infection
We used subgroup analysis to assess whether the use of different
types of interferon γ release assay (ELISpot and QuantiFERON)
led to different results.We also investigated the relation between
the observed effect of BCG and age at which BCG vaccination
was recommended in the area where the study was conducted
(we used policy recommendations because we did not have
timing of BCG vaccination in individuals); geographical latitude
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where the study was conducted: latitudes of the study location
was categorised into three groups: 0-20°, 20-40°, and >40°; and
study quality: we investigated the effect of study quality by
application of the Newcastle-Ottawa scale.15 Using this scale,
we compared studies with a point rating on this scale equal or
above and below the median of 5 points.
Secondary analysis—protection against infection
protection against disease
In a secondary analysis, we estimated protection by BCG against
active disease in a subset of six studies that reported
development of active tuberculosis during screening. This was
achieved by examining, in this subset, the number of children
with active disease (regardless of assay status) in those who
received BCG versus those who did not. In the population with
tuberculosis infection determined from positive result on
interferon γ release assays, we also examined the effect of BCG
on progression from infection to early active disease by
comparing the number with active disease in those who received
BCG versus those who did not.
Statistical analysis
Analysis was performed with the DerSimonian and Laird
random effects model, which incorporates variation between
studies in the weighting. To quantify inconsistency across
studies by describing percentage of the variability in effect
estimates from heterogeneity we used the I2 statistic with I2
>40% representing moderate, >60% substantial, and >80%
considerable heterogeneity.17We applied a continuity correction
to zero cells to include all studies in the analysis; the approach
used is designed to minimise bias,16 although in our case the
potential bias from any such correction would be extremely
small as only one study contained zero counts and there were
plenty of well powered studies. We assessed potential factors
behind the heterogeneity with random effects meta-regression.18
The protective effect of BCGwas described with risk ratios and
95% confidence intervals. To assess potential publication bias
we used funnel plots and the Harbord test.19
Results
Study selection
Our literature search found 601 articles; based on a review of
titles, we selected 546 abstracts for further assessment leading
to the identification of 133 articles for full text review (fig 1).⇓
After we reviewed the full text, 112 articles did not meet the
inclusion criteria. The 21 remaining articles (describing 21
studies) were selected for potential inclusion. Fourteen articles
stated that interferon γ release assays were carried out but did
not report the results on the relation between BCG vaccination
and assay. The authors were contacted and asked to provide the
raw data. For seven such studies, we received no response after
repeated attempts. The analysis therefore included 14 studies
(fig 1).⇓
Characteristics of included studies
Themeta-analysis included cohort studies of children who were
screened as part of an investigation of a tuberculosis
outbreak,11 12 20-22whowere referred to hospital as close contacts
of index cases,20 21 23-25 were household contacts of an infectious
adult,13 26-28 or were contacts in other settings.29 Four studies
were conducted in the United Kingdom, two each in the Gambia
and Spain, and a single study in Greece, Italy, Indonesia, Turkey,
South Africa, and Cambodia each (table).⇓ BCG vaccination
status was assessed in included studies by one or a combination
of BCG scar,12 13 22-27 29 30 confirmed medical records,11 12 21 30 and
parental recall of vaccination.21
In 13 of the 14 studies patients in the index cases had smear
positive active tuberculosis. In one additional study the index
case was a patient with smear negative pulmonary tuberculosis.
This was a 9 year old child in whom the duration of exposure
of contacts at school was for a long unspecified period of time.11
Primary analysis
Our primary analysis with 14 studies and 3855 participants
estimated an overall risk ratio of 0.81 (95% confidence interval
0.71 to 0.92, random effects estimate, fig 2)⇓, indicating 19%
protective efficacy against tuberculosis infection among
vaccinated children after exposure compared with unvaccinated
children. We noted moderate heterogeneity (I2=40 %, P<0.06)
between the studies. All studies included
non-immunocompromised populations, with low probability
that specific cut off values are required. The observed protection
was similar for the two types of assay: ELISpot (risk ratio 0.83,
95% confidence interval 0.68 to 1.02; four studies) and
QuantiFERON (0.78, 0.64 to 0.96; 10 studies) (fig 3).⇓
Eight of the 10 Quantiferon studies used Quantiferon In Tube
Gold, which includes a further antigen (TB7.7). Further
stratification by ELISpot, Quantiferon, and Quantiferon In Tube
showed no evidence of inconsistency (data not shown). In eight
studies, the cut off for positive assay result was 0.35 IU/mL or
they reported using the manufacturer’s; one used a cut off of
10 IU/mL29 and one provided no information—omission of this
study does not alter the conclusion.
Subgroup analysis: variables affecting
protection against infection
Figure 4 shows a summary of the subgroup analysis by study
characteristics.⇓ Within subgroups for latitude there was
moderate heterogeneity; and we found greater protection at
higher latitudes, although the difference in protection by latitude
was not significant in meta-regression (P=0.56, fig 4).⇓ Studies
conducted above 40° latitude showed a protective efficacy of
BCG vaccination of 26% (risk ratio 0.74, 95% confidence
interval 0.60 to 0.91), while studies conducted at lower latitudes
of 20-40° (0.88, 0.54 to 1.45) and 20-0° (0.87, 0.72 to 1.04) (fig
A, appendix 1) showed no evidence of a protective effect.
Subgroup analysis comparing areas according to recommended
age of BCG vaccination (fig B, appendix 1) showed no evidence
for a difference in efficacy according to vaccination policy:
where the policy was not to vaccinate at birth, protection by
BCG against M tuberculosis infection was effective (risk ratio
0.72, 95% confidence interval 0.56 to 0.93); and in other areas
it was not as effective (0.85, 0.73 to 0.98), with meta-regression
giving a P value of 0.27. It was difficult to distinguish between
effects of vaccination policy and region.
Exposure to tuberculosis
About half (48%) of the children (n=1862, five studies11-13 20 21)
included were exposed to a single well defined source
simultaneously or it was known that there was no difference in
exposure.13 A subgroup analysis of these studies found a higher
vaccine efficacy of 28% (risk ratio of 0.73, 95% confidence
interval 0.52 to 1.00).
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Study quality
Based on a modified Newcastle-Ottawa scale, we considered
three studies to be of high quality, eight of moderate quality,
and three of low quality (table⇓ and see appendix 2 for details).
Five articles provided information on degree of exposure to
infectious cases.11-13 27 29 Three articles reported that BCG
vaccination was given at birth,13 26 27while the remaining articles
did not provide time of vaccination. Two of the articles provided
precise information on the timing of interferon γ release assay
relative to presumed exposure to an infectious case.12 27 Three
of the 14 studies included stated that the association between
BCG vaccination and a negative assay result was primary or
secondary outcome.11-13 The study question in Soysal and
colleagues was whether BCG vaccination affects the risk of
infection in children exposed to tuberculosis.13 The study of
Eisenhut and colleagues was carried out during a school
outbreak11 and the study by Eriksen and colleagues during a
nursery outbreak12; in both the primary aim was to assess
whether BCG vaccination had a protective effect against M
tuberculosis infection. In two of the articles included the
investigators were blinded.13 22 In one study, clinical diagnosis
of tuberculosis was made without the assay results, and the
researchers in the laboratory did not see the clinical data before
the tests were carried out.22 In the second study, people who
performed and read the assays were blind to all personal
identifiers and results of tuberculin skin tests.13 Most studies
(n=10) were able to show adequate follow-up of exposed
children until the interferon γ release assays, with few or no
children lost to follow-up between presumed exposure to an
infectious case and application of the assay.
We compared studies with a quality rating of 3-4 with those
with a rating of ≥5 (fig C, appendix 1). Studies with a rating of
≥5 showed protection (risk ratio 0.68, 95% confidence interval
0.55 to 0.84) and those with a rating of 3 or 4 didn’t (0.88, 0.77
to 1.01); (P value for difference 0.06; fig 4)⇓. This explained
16.4% of heterogeneity between studies (residual heterogeneity
I2=24%)
Publication bias assessment
The funnel plot in figure 5⇓ showed no evidence of publication
bias, and the Harbord test gave a P value of 0.69).19 One study
was dropped from this analysis because of a number of cells in
the table with zero observations.21
Secondary analysis—protection against
infection v protection against disease
We conducted an analysis of six studies that reported the number
of people who progressed to active tuberculosis disease during
screening.11-13 23 27 29 This additional information allowed us to
estimate the protective effect of BCG immunisation against
infection; the overall protective effect against active
tuberculosis; and the protective effect against progression from
M tuberculosis infection to active disease (fig 6)⇓. Interferon γ
release assay status was not considered (whether performed or
not) when we calculated the number of those who developed
active tuberculosis within the population. In these six studies,
the protection against infection (in all children, irrespective of
whether they went on to develop disease) was 27% (risk ratio
0.73, 95 % confidence interval 0.61 to 0.87; fig 7⇓) and
protection against active tuberculosis was 71% (0.29, 0.15 to
0.58). Protection by BCG against progression from infection to
active disease, calculated by using infected individuals, was
58% (0.42, 0.23 to 0.77; fig 6 and fig 7).⇓⇓
Discussion
Principal findings
This systematic review shows that BCG vaccination can protect
against M tuberculosis infection and consolidates the results
from recent studies showing evidence of protection against
infection.11-13 29 Our results support a paradigm shift in the
understanding of how antimycobacterial vaccines (new and old)
can work, from the view that BCG protects against disease but
not against infection to one that it protects against infection
itself.31
A recent double blind randomised placebo controlled phase 2b
trial of a BCG prime-MVA85A boost vaccination in infants
showed no evidence of additional protection, over and above
that of BCG against tuberculosis disease infection.32 This is
despiteMVA85A inducing a significantly higher Ag85-specific
CD4 positive T cell expression of interferon γ, TNFα, and
interleukin 2 compared with placebo. One possible explanation
for this lack of increased efficacy might be that BCG conferred
protection againstM tuberculosis infection was sufficiently high
such that an additional immunisation withMVA85Awas unable
to confer additional protection.
The observed protection against M tuberculosis infection was
independent of the assay method used for measurement. There
was no evidence of protection against infection less than 40°
latitude away from the equator, although the number of studies
was small and the difference was not significant. If this finding
is confirmed, then the effect of latitude would be consistent with
the variation in protection by BCG against pulmonary disease.8
In this case, the mechanism here could be the same: that the
higher prevalence of non-tuberculous mycobacterial infection
close to the equator decreases the measured protection with
BCG. The limited number of studies reviewed from locations
closer to the equator, however, means that firm conclusions
must wait until new studies find similar results.
High quality studies also showed protection by BCG vaccination
against infection, while lower quality studies did not suggest
that study design factors in smaller low quality studies led to
the inability to detect a protective effect. This has been observed
in systematic reviews of trials of BCG vaccination against
tuberculosis.8
We found evidence of progression to active tuberculosis as
identified at point of screening of index cases. Our interpretation
of progression at the time of screening potentially includes both
early and late progressors because of uncertainty of the timing
of progression to active disease. Publication of an analysis of
follow-up data from a study used in this meta-analysis13 recently
reported protective efficacy of the vaccine of 67% for protection
against progression from infection to active disease.33 Similar
longitudinal cohorts and randomised control trials will provide
a better understanding of the protective efficacy of BCG
vaccination.
Limitations and strengths
Our results should be treated with caution for several reasons.
Data were not always complete, and we could not control for,
or explore interaction with, all variables. For instance, it was
assumed there was no prior infection before the documented
exposure to active disease or outbreak. Such exposure, however,
should affect vaccinated and unvaccinated children equally.
Vaccinated children are unlikely to be different from
unvaccinated children in other ways that could contribute to
protection from infection.We attempted to lower the probability
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of prior exposure by restricting the analysis to children aged
under 16.
We tried to minimise bias from differences in exposure in the
two groups by limiting the review to studies among
contacts—that is, to outbreaks among contacts of infectious
cases or known household exposure where exposure is likely
to be similar in vaccinated and unvaccinated children. It is
important, however, to consider the possibility that studies
included in this review had vaccine recipients who were less
likely to be exposed to infection before the outbreak. Exposure
can differ because of variable duration of infectiousness of the
index patient and the amount of effective contact.
Reduced infection rates in children immunised with BCG could
also be caused by the fact that parents who are generally more
aware of infection control measures are from higher educated
families with lower exposure to M tuberculosis infection and
have their children more comprehensively immunised, which
includes BCG immunisation. A further potential source of bias
relates to the greater likelihood that private paediatricians who
care for children from medium and high socioeconomic levels
might recommend against BCG vaccination if they consider
these children to be at a lower risk of infection. We included
various observational studies from settings with different
socioeconomic backgrounds, potentially neutralising such bias.
We also acknowledge that further quantification of degree of
exposure to tuberculosis cases, including proximity to the index
case and the number of cases in close contact, was not possible
in our study because the primary studies were not designed to
compare exposure in childrenwhowere andwere not immunised
with BCG.
Investigation of the effect of age at vaccination at an individual
level and of time from vaccination to exposure to an infectious
case would be of particular interest. The use of interferon γ
release assays as an indicator of infection is still subject to some
debate, although this is currently the best marker for infection
and certainly discriminates well between infection with M
tuberculosis and previous BCG vaccination.
There are suggestions that different strains of BCG can induce
a broad range of immunological response, which in turn brings
about a change in the level of protection. A recent meta-analysis
of trials, including 18 studies reporting on protection against
pulmonary and six reporting on protection against miliary or
meningeal tuberculosis, showed no evidence that efficacy of
BCGwas associated with vaccination strains.8 These results are
consistent with results from the UKMRC trials, which found
equivalent protection by the Copenhagen strain of BCG and an
M microti derived vaccine.6 Only three11 13 27 of the 14 studies
included in our review provided information on the BCGvaccine
strains used, so we also used the UK studies11-13 20 21 27 from
which we had information on the strains of BCG used in British
school children and found no evidence of bias by vaccine strain
(data not shown).
We limited subgroup analyses to investigate heterogeneity
because of the potential for spurious findings. Where assessed,
the main differences in the subgroup analyses were for rating
on the Newcastle-Ottawa scale, the P value for which was
similar under the permutation test recommended by Higgins
and Thompson.17 Similarly, the small number of studies limited
the power to explore whether the variation in protection by BCG
against tuberculosis is mostly through variation in protection
against infection. The primary aim of most (75%) studies
reviewed was not to investigate BCG protection against
infection. This, taken in combination with our symmetrical
funnel plot, suggests that our findings are unlikely to be caused
by publication or reporting bias.
Implications and conclusions
The effect of BCG vaccination, and its policy implications,
would be different for countries with high versus low incidence
of tuberculosis especially in terms of the cost effectiveness of
policies. Countries with a policy of vaccination at birth tend to
be those countries with a higher incidence of tuberculosis (cut
off >20/100 000 according to European Centre for Disease
Prevention (ECDC)) than those countries without such
vaccination policy (<20/100 000). Given the incomplete control
of tuberculosis, especially in high burden countries, optimisation
of use of BCG is sensible. Our analysis supports vaccinating
children as soon as possible after birth to prevent infection and
disease.
Our results provide evidence that BCG protects against
tuberculosis infection frommultiple epidemiologically different
settings and independent of the type of interferon γ release assay
used to detect infection. Future trials of candidate vaccines need
to investigate the efficacy of the new vaccine against
tuberculosis infection and early progression and late progression
to active disease. In addition, transparent reporting from
outbreak and contact studies of individual ages and time of
vaccination and exposure to tuberculosis of participants should
allow future meta-analysis to investigate protection against
infection. Our results also suggest that models of BCG impact
should be revised to include an effect against infection and
consequently latent M tuberculosis infection and reactivation
as without this the effect of BCG would be underestimated.
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Table
Table 1| Characteristics of studies included in systematic review of effect of BCG vaccination against mycobacterium tuberculosis infection
in children
Quality rating*Age group (years)
No of
participantsSettingCountryStudy period
Moderate6 months-14236†Childhood household contactsGambiaNSAdetifa 2010
Moderate<15166Contacts with smear positive active TB
patient
SpainSept 2005-Sept 2007Altet-Gomez 2011
Moderate<1618†Referred to hospital as close contacts of
index cases
Italy1 July 2005-31 December
2006
Bianchi 2009
Moderate0-16117Individuals registered as close contacts of
patients
SpainSept 2004-Nov 2006Domingues 2008
Moderate7-10199Outbreak investigationUK2007Eisenhut 2009
High0-9126Outbreak investigation—nurseryUK2009Eriksen 2010
Moderate11-15535School outbreak studyUK2001Ewer 2003
Low0-14643†Child contacts of patient with sputum smear
positive tuberculosis
GambiaJune 2002-September
2004
Hill 2006
Moderate0-5195†Young children living with pulmonary TB
patients
Cambodia2005Okada 2008
Low9 months-9330Exposed to household and neighbourhood
index cases
IndonesiaNSRutherford 2012
High0-16979Child household contacts of adults with smear
positive pulmonary tuberculosis
TurkeyOctober 2002-April 2003Soysal 2005
HighMedian 1323School bus passengers (driver of bus was
index case)
UK2007Neira-Munoz 2008
Moderate5-15159†Household contacts of index casesSouth AfricaNSTsiouris 2006
Low<15129†Contacts with adult with TB who attended TB
clinic
Greece1 Jan 2007-31 December
2008
Tsolia 2010
NS=not specified.
*Newcastle-Ottawa scale rating: high >66.6%; moderate 33.3-66.6%; low <33.3%.
†Data received from author.
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Figures
Fig 1 Study selection for systematic review of BCG vaccination against mycobacterium tuberculosis infection in children
Fig 2 Protection against Mycobacterium tuberculosis infection (TB) as determined by interferon γ release assay
(QuantiFERON) in children vaccinated with BCG. D+L=DerSimonian and Laird method; M-H=Mantel-Haenszel method.
One test was used per paper and in cases where both ELISpot and QuantiFERON data were available data from
QuantiFERON testing were used
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Fig 3 Protection against Mycobacterium tuberculosis infection (TB) as determined by interferon γ release assay (ELISpot
v QuantiFERON) in children vaccinated with BCG. D+L=DerSimonian and Laird; M-H=Mantel-Haenszel
Fig 4 Subgroup analyses of protection in children by BCG vaccination against Mycobacterium tuberculosis infection (TB)
in children vaccinated with BCG, as determined by type of interferon γ release assay, latitude, study quality, and age at
vaccination policy comparing areas with (A) and without (B) policy to vaccinate infants at birth; and separate analysis of
protection against active disease and against progression from infection to disease in subset of studies (DerSimonian and
Laird method)
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Fig 5 Funnel plot (with pseudo confidence intervals) of studies investigating association between BCG vaccination and
result of interferon γ release assay
Fig 6 Schematic representation of protective effect of BCG immunisation against Mycobacterium tuberculosis infection,
active tuberculosis, and progression to active tuberculosis from infection during screening from subset of six articles with
data on active tuberculosis (vaccine efficacy (VE) and 95% confidence intervals)
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Fig 7 Types of protection against Mycobacterium tuberculosis (TB) in children vaccinated with BCG: protection against
infection (irrespective of whether they went on to develop active TB); overall protection against active TB; protection against
progression from infection to active TB during screening. D+L=DerSimonian and Laird method; M-H=Mantel-Haenszel
method
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